Rapid Clinical and Radiologic Responses With Larotrectinib Treatment in a Patient With TRK-Fusion-Positive Metastatic Lung Cancer

被引：3

作者：

Hochmair, Maximilian Johannes ^{[1
]}

Setinek, Ulrike ^{[4
]}

Krenbek, Dagmar ^{[2
,4
]}

Fazekas, Andreas ^{[1
]}

Illini, Oliver ^{[1
]}

Weinlinger, Christoph ^{[1
]}

Draxler, Hermann ^{[1
]}

Marcher, Markus ^{[3
]}

Valipour, Arschang ^{[1
]}

Muellauer, Leonhard ^{[5
]}

Beer, Lucian ^{[6
,7
]}

机构：

[1] Krankenhaus Nord, Dept Resp & Crit Care Med, Karl Landsteiner Inst Lung Res & Pulm Oncol, Brunner Str 68, A-1210 Vienna, Austria

[2] Krankenhaus Nord, Klin Floridsdorf, Dept Pathol, Vienna, Austria

[3] Krankenhaus Nord, Klin Floridsdorf, Dept Thorac Surg, Vienna, Austria

[4] Wilhelminenspital Stadt Wien, Dept Pathol, Vienna, Austria

[5] Med Univ Vienna, Inst Pathol, Vienna, Austria

[6] Med Univ Vienna, Dept Biomed Imaging & Image Guided Therapy, Vienna, Austria

[7] Dept Radiol & Canc Res UK, Cambridge, England

来源：

CLINICAL LUNG CANCER | 2020年 / 21卷 / 02期

关键词：

Case report; Entrectinib; Rare oncogenic driver; Tropomyosin receptor kinase fusion; TRK inhibition; DOCETAXEL; ONCOGENE; EFFICACY;

D O I：

10.1016/j.cllc.2019.11.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Tropomyosin receptor kinase (TRK) fusion oncoproteins are found in approximately 1% of all solid tumors. Selective TRK inhibitors such as larotrectinib have been developed to target TRK fusions in a variety of cancers including lung cancer. Several TRK inhibitors are currently in clinical development, including next-generation agents that can overcome acquired resistance. In the clinical trial setting, larotrectinib has shown marked and durable antitumor activity. The case of a female never smoker who was diagnosed with metastatic lung cancer at the age of 30 years illustrates that molecular testing including NTRK gene fusions can be life-saving. It thus appears reasonable to routinely perform comprehensive genomic profiling after the diagnosis of adenocarcinoma of the lung. The clinical characteristics of patients who tend to develop NTRK rearrangements remain to be determined. (C) 2019 Elsevier Inc. All rights reserved.

引用

页码：E49 / E53

页数：5

共 16 条

[1] NTRK gene fusions as novel targets of cancer therapy across multiple tumour types [J].

Amatu, Alessio ;

Sartore-Bianchi, Andrea ;

Siena, Salvatore .

ESMO OPEN, 2016, 1 (02)

[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[3] Neurotrophins and their receptors: A convergence point for many signalling pathways [J].

Chao, MV .

NATURE REVIEWS NEUROSCIENCE, 2003, 4 (04) :299-309

[4] NTRK fusion-positive cancers and TRK inhibitor therapy [J].

Cocco, Emiliano ;

Scaltriti, Maurizio ;

Drilon, Alexander .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) :731-747

[5] Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children [J].

Drilon, A. ;

Laetsch, T. W. ;

Kummar, S. ;

DuBois, S. G. ;

Lassen, U. N. ;

Demetri, G. D. ;

Nathenson, M. ;

Doebele, R. C. ;

Farago, A. F. ;

Pappo, A. S. ;

Turpin, B. ;

Dowlati, A. ;

Brose, M. S. ;

Mascarenhas, L. ;

Federman, N. ;

Berlin, J. ;

El-Deiry, W. S. ;

Baik, C. ;

Deeken, J. ;

Boni, V. ;

Nagasubramanian, R. ;

Taylor, M. ;

Rudzinski, E. R. ;

Meric-Bernstam, F. ;

Sohal, D. P. S. ;

Ma, P. C. ;

Raez, L. E. ;

Hechtman, J. F. ;

Benayed, R. ;

Ladanyi, M. ;

Tuch, B. B. ;

Ebata, K. ;

Cruickshank, S. ;

Ku, N. C. ;

Cox, M. C. ;

Hawkins, D. S. ;

Hong, D. S. ;

Hyman, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (08) :731-739

[6]

Drilon AE, 2019, J CLIN ONCOL S, V37

[7] Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions [J].

Hechtman, Jaclyn F. ;

Benayed, Ryma ;

Hyman, David M. ;

Drilon, Alexander ;

Zehir, Ahmet ;

Frosina, Denise ;

Arcila, Maria E. ;

Dogan, Snjezana ;

Klimstra, David S. ;

Ladanyi, Marc ;

Jungbluth, Achim A. .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2017, 41 (11) :1547-1551

[8] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

[9]

HONG DS, 2019, J CLIN ONCOL S, V37

[10]

Lassen UN, 2018, ANN ONCOL, V29, P133

← 1 2 →